Cabozantinib for Patients With Recurrent or Progressive Meningioma
Trial Parameters
Brief Summary
A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
Eligibility Criteria
Inclusion Criteria 1. Histologic (preferred) or radiologic diagnosis of meningioma. All World Health Organization (WHO) grades (I, II and III) are allowed. 2. All patients must have developed recurrent disease or progressive disease after receiving standard therapy (e.g., radiation or surgery) \> 6 months ago or have been deemed ineligible to receive these therapies. 3. Karnofsky Performance Status ≥ 50. 4. Adequate hematologic function: 1. Absolute Neutrophil Count ≥ 1.5 x 10\^9 / L without granulocyte colony-stimulating factor support. 2. Platelet Count ≥ 100 x 10\^9 / L without transfusion. 3. Hemoglobin ≥ 9 g/dL without transfusion within 7 days prior to screening assessment. 5. Adequate renal function: ≥ 30 ml/min according to the Cockcroft-Gault formula. 6. Adequate hepatic function including: 1. Total bilirubin ≤ 1.5 x upper limit of normal (ULN). 2. Aspartate transaminase (AST) ≤ 3 x ULN without liver metastasis. 3. Alanine transaminase (ALT) ≤ 3 x ULN without liver metastasis.